Prime Medicine focused on advancing its in vivo liver franchise and engaging with the FDA for PM359 in CGD. While the company reported a net loss for the year, it maintained a solid cash position of $191.4 million and is preparing for multiple IND/CTA filings in 2026.

Prime Medicine's Q3 2025 performance reflected steady pipeline advancement and disciplined expense management, though the company remains in a net loss position as it progresses its preclinical and early-stage programs.

Prime Medicine reported a net loss of $51.9 million for the first quarter of 2025, an increase from $45.8 million in the same period last year. The company saw an increase in both R&D and G&A expenses, primarily due to expansion of laboratory space and personnel. Despite the loss, Prime Medicine is advancing its clinical programs, with initial data from its PM359 trial expected in 2025 and IND/CTA filings for Wilson's Disease and AATD targeted for 2026.

Prime Medicine reported a net loss of $195.9 million for the full year ended December 31, 2024, with total revenue of $2.983 million. The company is on track to report initial clinical data for PM359 in 2025 and expects to file an IND/CTA for PM577 in the first half of 2026. Cash and cash equivalents increased to $204.5 million.

Prime Medicine reported a net loss of $52.5 million for the third quarter of 2024. They received $110 million upfront from Bristol Myers Squibb through a strategic research collaboration. Pro-forma cash, cash equivalents, and investments are expected to fund operations into 1H 2026.

Prime Medicine reported a net loss of $55.3 million for the second quarter of 2024. They achieved a key milestone with FDA clearance to advance PM359 into clinical trials and are initiating Phase 1/2 clinical trial. The company is also advancing multiple programs and expects to share new preclinical data.

Prime Medicine reported a net loss of $45.8 million for the first quarter of 2024, compared to a net loss of $39.4 million for the same period in 2023. The company's cash, cash equivalents, investments, and restricted cash totaled $224.2 million as of March 31, 2024. Key achievements include the FDA clearance of the IND application for PM359 and the presentation of new preclinical data showcasing the potential of Prime Editing technology.

Prime Medicine reported its full year 2023 financial results, highlighting its progress in advancing its Prime Editing platform and therapeutic programs. The company is on track to file an IND application or CTA for PM359 in the first half of 2024, with initial data expected in 2025. Additionally, Prime Medicine completed an upsized $161 million public offering.

Prime Medicine reported a net loss of $50.7 million for the third quarter ended September 30, 2023. The company's cash, cash equivalents, investments and restricted cash were $178.8 million as of September 30, 2023, which is expected to fund operating expenses and capital expenditure requirements through the end of 2024.

Prime Medicine reported a net loss of $42.4 million for the second quarter of 2023. As of June 30, 2023, cash, cash equivalents, investments and restricted cash were $221.1 million. The company expects these funds to be sufficient to fund operating expenses and capital expenditure requirements into 2025.